Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of NWRD09 in Patients With HPV16-Positive Cervical High-Grade Squamous Intraepithelial Lesion (HSIL)

NCT07712692 is registered in ClinicalTrials.gov with Newish Biotech (Wuxi) Co., Ltd. as lead sponsor.

NCT NCT07712692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07712692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of NWRD09 in Patients With HPV16-Positive Cervical High-Grade Squamous Intraepithelial Lesion (HSIL)
Lead sponsor
Newish Biotech (Wuxi) Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 30, 2027
Enrollment
156 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade squamous intraepithelial lesion (hsil)